GHB, or gamma-hydroxybutyrate, is a treatment used for the management of cataplexy. However, it has also gained controversy as a drug of misuse and has been linked to several social and legal issues. As a result, many countries have established rules to control the distribution of GHB.

In the United States, GHB was listed as a most restrictive classification in 1990, which is the most restrictive restrictive classification according to US federal law. However, in 2002, GHB was rescheduled to a higher schedule classification, which allowed for certain therapeutic uses, including the management of cataplexy. This change in scheduling status was made due to the development of new models and the implementation of safety measures to minimize the risk of misuse.

In the United Kingdom, ghb online kaufen is classified as a lesser category under the Misuse of Drugs Act 1971, which means that transferring GHB without a legitimate license can result in sentence. Class C substances are considered to be the lesser serious of the controlled substances, but infractions involving GHB can still carry penalties of up to 14 years in prison.

In Canadians, GHB was listed as a most restrictive classification under the Controlled Drugs and Substances Act in 2003, which gave the Canadian government the authority to regulate its sale. In order to obtain GHB, Canadians typically require a license from a licensed medical practitioner, which is necessary for legitimate treatment of cataplexy.

In Australia, GHB is classified as a most restrictive scheduling category, which is the least restrictive scheduling category under state and federal laws. This classification prohibits the sale of GHB except for therapeutic purposes, and distribution without a license can lead to lengthy prison sentences.

In the Germans, GHB is classified as a Betäubungsmittel Tier 2 substance, which places it under heavier restrictions than substances classified as Tier 3 but lesser restrictions than Tier 1 substances. The possession of GHB in Germany requires a permit from the regulatory authorities, and non-medical use can result in sentence and imprisonment.

In European Union, GHB is considered a dependency-forming drug under the Loi du 31 décembre 1970, which means that it has great health risks, and as such is regulated and available by prescription and license, outside specific use, possible consequences of arrest as recidivists 5 years may be handed. In Scandinavia, it is classified as a "strong drug" which essentially gives the same restrictive use such as drugs.

It is essential to note that the ever-shifting political and atmosphere often gives health organizations and legal regulatory commissions much to debate. Under such deliberations GHB, often for specific purposes is discovered to be of growing use, and also, that many current restrictions can often be proven to be eventually ineffective. As existing studies and evidence evolve around GHB they find support supporting GHB's range in possible therapeutic uses worldwide, a discussion ultimately that calls for continued reflection and communications in society, including strictness and alteration as appropriate legal responses.